Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance

Cancer cells are subjected to constant selection by the immune system, meaning that tumors that become clinically manifest have managed to subvert or hide from immunosurveillance. Immune control can be facilitated by induction of autophagy, as well as by polyploidization of cancer cells. While autophagy causes the release of ATP, a chemotactic signal for myeloid cells, polyploidization can trigger endoplasmic reticulum stress with consequent exposure of the “eat‐me” signal calreticulin on the cell surface, thereby facilitating the transfer of tumor antigens into dendritic cells. Hence, both autophagy and polyploidization cause the emission of adjuvant signals that ultimately elicit immune control by CD8+ T lymphocytes. We investigated the possibility that autophagy and polyploidization might also affect the antigenicity of cancer cells by altering the immunopeptidome. Mass spectrometry led to the identification of peptides that were presented on major histocompatibility complex (MHC) class I molecules in an autophagy‐dependent fashion or that were specifically exposed on the surface of polyploid cells, yet lost upon passage of such cells through immunocompetent (but not immunodeficient) mice. However, the preferential recognition of autophagy‐competent and polyploid cells by the innate and cellular immune systems did not correlate with the preferential recognition of such peptides in vivo. Moreover, vaccination with such peptides was unable to elicit tumor growth‐inhibitory responses in vivo. We conclude that autophagy and polyploidy increase the immunogenicity of cancer cells mostly by affecting their adjuvanticity rather than their antigenicity.

[1]  L. Galluzzi,et al.  Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy , 2017, Nature Reviews Clinical Oncology.

[2]  S. Elledge,et al.  Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy , 2017, Science.

[3]  J. Kline,et al.  Calreticulin promotes immunity and type I interferon-dependent survival in mice with acute myeloid leukemia , 2017, Oncoimmunology.

[4]  L. Zitvogel,et al.  Immunogenic cell death in cancer and infectious disease , 2016, Nature Reviews Immunology.

[5]  G. Kroemer,et al.  Image Cytofluorometry for the Quantification of Ploidy and Endoplasmic Reticulum Stress in Cancer Cells. , 2017, Methods in molecular biology.

[6]  Mila Ljujic,et al.  The integrated stress response , 2016, EMBO reports.

[7]  M. Maiuri,et al.  Autophagy induction for the treatment of cancer , 2016, Autophagy.

[8]  F. Di Virgilio,et al.  Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. , 2016, Cancer cell.

[9]  C. Münz Autophagy proteins in antigen processing for presentation on MHC molecules , 2016, Immunological reviews.

[10]  L. Zitvogel,et al.  Immunological off-target effects of imatinib , 2016, Nature Reviews Clinical Oncology.

[11]  L. Zitvogel,et al.  Microbiome and Anticancer Immunosurveillance , 2016, Cell.

[12]  Nicolai J. Birkbak,et al.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.

[13]  L. Zitvogel,et al.  The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer , 2016, Autophagy.

[14]  Lisa M. Coussens,et al.  The Basis of Oncoimmunology , 2016, Cell.

[15]  J. Zucman‐Rossi,et al.  Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. , 2016, Advances in immunology.

[16]  L. Zitvogel,et al.  Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1 , 2015, Science.

[17]  O. Kepp,et al.  Morphometric analysis of immunoselection against hyperploid cancer cells , 2015, OncoTarget.

[18]  L. Zitvogel,et al.  Combined evaluation of LC3B puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer , 2015, Autophagy.

[19]  T. van Hall,et al.  Alternative Antigen Processing for MHC Class I: Multiple Roads Lead to Rome , 2015, Front. Immunol..

[20]  T. Gajewski,et al.  Innate immune recognition of cancer. , 2015, Annual review of immunology.

[21]  J. Banchereau,et al.  Immunotherapy: The Path to Win the War on Cancer? , 2015, Cell.

[22]  P. Sharma,et al.  Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential , 2015, Cell.

[23]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[24]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[25]  Z. Modrušan,et al.  Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing , 2014, Nature.

[26]  Maxim N. Artyomov,et al.  Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens , 2014, Nature.

[27]  M. Delorenzi,et al.  Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy , 2014, Nature Medicine.

[28]  P. Vandenabeele,et al.  Consensus guidelines for the detection of immunogenic cell death , 2014, Oncoimmunology.

[29]  H. Rao,et al.  Synthesis and Characterization of 4-Aryl-4H-chromenes from H-Cardanol , 2014, Natural Product Communications.

[30]  O. Kepp,et al.  Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling , 2013, Cell Death and Differentiation.

[31]  L. Zitvogel,et al.  Molecular mechanisms of ATP secretion during immunogenic cell death , 2013, Cell Death and Differentiation.

[32]  L. Zitvogel,et al.  Autophagy and cellular immune responses. , 2013, Immunity.

[33]  J. Blay,et al.  Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. , 2013, Cancer research.

[34]  P. van Endert,et al.  Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. , 2013, Immunity.

[35]  Laurence Zitvogel,et al.  Immunogenic cell death in cancer therapy. , 2013, Annual review of immunology.

[36]  H. Clevers,et al.  Immunosurveillance against tetraploidization-induced colon tumorigenesis , 2013, Cell cycle.

[37]  S. Ryter,et al.  Autophagy in human health and disease. , 2013, The New England journal of medicine.

[38]  Abhishek D. Garg,et al.  Immunogenic cell death and DAMPs in cancer therapy , 2012, Nature Reviews Cancer.

[39]  Ming Li,et al.  An Immunosurveillance Mechanism Controls Cancer Cell Ploidy , 2012, Science.

[40]  R. Khanna,et al.  Autophagy mediates transporter associated with antigen processing-independent presentation of viral epitopes through MHC class I pathway. , 2012, Blood.

[41]  Hiroaki Tanaka,et al.  Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival , 2012, Nature Medicine.

[42]  L. Zitvogel,et al.  Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39 , 2012, Oncoimmunology.

[43]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[44]  F. Di Virgilio,et al.  Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice , 2011, Science.

[45]  Sébastien Lemieux,et al.  The MHC I immunopeptidome conveys to the cell surface an integrative view of cellular regulation , 2011, Molecular systems biology.

[46]  L. Galluzzi,et al.  Mitotic catastrophe: a mechanism for avoiding genomic instability , 2011, Nature Reviews Molecular Cell Biology.

[47]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[48]  R. Schreiber,et al.  Natural innate and adaptive immunity to cancer. , 2011, Annual review of immunology.

[49]  L. Zitvogel,et al.  Decoding Cell Death Signals in Inflammation and Immunity , 2010, Cell.

[50]  J. Pignon,et al.  Immunogenic death of colon cancer cells treated with oxaliplatin , 2010, Oncogene.

[51]  L. Zitvogel,et al.  Chemotherapy induces ATP release from tumor cells , 2009, Cell cycle.

[52]  Michael R. Elliott,et al.  Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance , 2009, Nature.

[53]  P. van Endert,et al.  Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death , 2009, The EMBO journal.

[54]  Philipp Koehn Decoding , 2012, Encyclopedia of Algorithms.

[55]  L. Zitvogel,et al.  The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death , 2008, Cell Death and Differentiation.

[56]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[57]  M. Bianchi DAMPs, PAMPs and alarmins: all we need to know about danger , 2007, Journal of leukocyte biology.

[58]  L. Zitvogel,et al.  Calreticulin exposure dictates the immunogenicity of cancer cell death , 2007, Nature Medicine.

[59]  L. Zitvogel,et al.  Cancer despite immunosurveillance: immunoselection and immunosubversion , 2006, Nature Reviews Immunology.

[60]  David Mackey,et al.  MAMPs and MIMPs: proposed classifications for inducers of innate immunity , 2006, Molecular microbiology.

[61]  L. Zitvogel,et al.  Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death , 2005, The Journal of experimental medicine.

[62]  W. Janssen,et al.  Cell-Surface Calreticulin Initiates Clearance of Viable or Apoptotic Cells through trans-Activation of LRP on the Phagocyte , 2005, Cell.

[63]  R. Paules,et al.  An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. , 2003, Molecular cell.

[64]  P. Matzinger The Danger Model: A Renewed Sense of Self , 2002, Science.

[65]  Takeshi Noda,et al.  LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing , 2000, The EMBO journal.

[66]  P. Endert Genes regulating MHC class I processing of antigen , 1999 .

[67]  P. van Endert Genes regulating MHC class I processing of antigen. , 1999, Current opinion in immunology.

[68]  P. Cresswell,et al.  Mechanisms of MHC class I--restricted antigen processing. , 1998, Annual review of immunology.